MAPT and Alzheimer disease: APOE4 carriers show lower levels of CSF Aβ, but no differences in Tau [70]; by integrating ATN classification for AD, a dose-dependent effect has been suggested, with ApoE phenotypes at higher risk of developing AD being associated with a lower CSF Aβ42/40 ratio [71].